WHY WE’RE HERE
Navigating the terrain of prescribing opioids and caring for patients who depend on them is a complex endeavor. The multifaceted challenges, from misuse and abuse to diversion and addiction, have cast a long shadow on our nation’s public health.
CO*RE’s comprehensive curriculum plays a pivotal role in empowering clinicians to confidently navigate the complexities of opioid analgesics, patient assessment, therapy initiation, modification, and discontinuation, therapy management, and the vital act of counseling for patients and their caregivers. We provide the knowledge and tools to consider different approaches to pain management, and if opioid analgesics are warranted, to discover that delicate balance between the potential risks and much-needed benefits, ensuring essential relief to patients under your care.
Notably, CO*RE has extended its reach, raising awareness of this public health imperative among over a million healthcare clinicians. This is our shared responsibility, a call to address this crisis with education, compassion, and unwavering commitment.
CO*RE MISSION STATEMENT
The CO*RE mission is to promote individual and population health and public safety through timely, evidence-based, outcome-oriented, and interprofessional education related to the comprehensive management of pain, addiction, and their comorbidities.
Prescription opioid pain relievers play a crucial role in improving the quality of life for millions of Americans living with acute or chronic pain. However, misuse, diversion, addiction, and overdose of these medications have led to a severe public health epidemic in the United States. Since 1999, more than 960,000 people have died from opioid overdoses, with 81,083 deaths in 2023 alone. Opioids, primarily prescription pain relievers, heroin, and fentanyl, are the primary substances involved in these fatalities.
This public health crisis affects all regions of the country, transcending socioeconomic groups and ethnicities. In response, the federal government and the Food & Drug Administration (FDA) have intensified efforts to ensure safer opioid prescribing practices. CO*RE offers continuing education to healthcare professionals, aligning with the FDA’s mission and the FDA Blueprint (October 2023) for safe opioid prescribing.
FUNDER INFORMATION
This educational activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC). This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration. Click here for more information about the Opioid Analgesics REMS.